Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06991608

A Study to Compare Digital Disease Monitoring of Patients With csU (Telemedicine to Face-to-Face Visits) in Germany

This is a multicenter, non-randomized, non-interventional two-cohort study with prospective collection of primary data on monitoring of Chronic spontaneous urticaria (CSU) patients by telemedicine or F2F visits in routine clinical care. This implementation science study will collect data from patients during routine CSU monitoring via F2F visits or teledermatological visits. The study will be representative for the real-world patient CSU population in Germany.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Novartis Investigative Site, Hamburg, Free and Hanseatic City of Hamburg, Germany

Loading trial locations.

About this study

This study will investigate the effect of digital monitoring via teledermatology on patient-reported outcomes (PRO) usage in CSU. The automatic provision of PROs at each digital patient-physician contact will allow simple and time-efficient documentation of current symptoms and might improve patients care.

This study seeks to assess the impact of regular teledermatology-based monitoring on the utilization frequency of PROs in patients with CSU, as compared to the in-person visits F2F. Furthermore, the study aims to gauge the adaption, quality and assessibility of teledermatology of both health care providers and patients .

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults aged 18 and above
  • Written informed consent for participation obtained from the subject
  • Diagnosed chronic spontaneous urticaria
  • Medical therapy for CSU
  • Concomitant chronic inducible urticaria is allowed
  • Willing and be able to perform digital visits

Exclusion criteria

  • Simultaneous participation in any clinical trial

Treatment and study plan

collection of patient data

Other

This non-interventional study and will not influence treatment decisions

Primary outcomes

  1. Average number of UCT usage per patient

    Time frame: 52 weeks

    Average number of urticaria control test (UCT) usage per patient over the course of 52 weeks will be assessed in the teledermatology arm and in the F2F arm

  2. Total number of contacts per patient

    Time frame: 52 weeks

    Total number of contacts per patient over the course of 52 weeks

  3. Time interval in between visits per patient

    Time frame: 52 weeks

    Time interval in between visits per patient over the course of 52 weeks

  4. Average number of visits in F2F arm

    Time frame: 52 weeks

    Average number of visits in face to face (F2F) arm over the time course of 52 weeks

  5. Average number of contacts in digital arm

    Time frame: 52 weeks

    Average number of contacts in digital arm (stratified for type of contact (video, chat)) over the time course of 52 weeks

  6. Median time of patients in the medical department in F2F arm

    Time frame: 52 weeks

    Median time of a patients in the medical department (time between entry and exit of the office)

  7. Median time of a patient for each digital contact in the digital arm

    Time frame: 52 weeks

    Median time of a patient for each digital contact stratified for type of contact (total time of video call, total time for chat messages)

  8. Score of urticaria control test [UCT]

    Time frame: Baseline, week 52

    UCT is a four-item questionnaire to assess symptom control and quality of life. Each question will be rated from 0 points (no control) to 4 (very well controlled) resulting in a final score from 0 (no disease control) to 16 (complete control)

  9. Score of urticaria activity test 7 [UAS7]

    Time frame: Baseline, week 52

    The UAS7 is a weekly score built up by the sum of hives (wheals; measured via hive severity score [HSS7]) and itch (itch severity score [ISS7]) over one week. For assessment of HSS7, the patient will record the number of wheals twice daily (0 (no hives), 1 (1-6 hives), 2(7-12 hives), 3 (> 12 hives) and the final score is added at the end of the week. To calculate the weekly ISS7, the patient will rate the severity of itch twice daily according to a numeric scale (0 (none) to 3 (severe)). The UAS7 is the sum of the HSS7 score and the ISS7 score. The possible range of the weekly UAS7 score is 0 - 42 (highest activity).

  10. score of dermatology life quality index [DLQI]

    Time frame: Baseline, week 52

    The DLQI is a 10-item general dermatology disability index designed to assess health-related quality of life (HRQoL) in adult subjects with skin diseases such as eczema, psoriasis, acne, and viral warts. Participants rate their dermatology symptoms as well as the impact of their skin condition on various aspects of their lives thinking about the previous 7 days. An overall score is calculated and ranges from 0 to 30 (higher score meaning worse disease related QoL)

  11. Survey to assess satisfaction with current consultations for HCPs and patients

    Time frame: Baseline, week 52

    Participants and their treating HCPs will answer questionnaires assessing their satisfaction with current consultations (retrospectively), as well as satisfaction with the consultation assigned during the study (arm A or arm B). The survey covers questions regarding (digital) disease monitoring and their usefulness/effectiveness in the disease indication of csU, usage of (electronic) PROs and their acceptance in clinical practice, time aspects of the two consultation types, etc.

Sponsors and collaborators

Lead sponsor

Novartis Pharmaceuticals

Industry

Registry information

Official study title

A Non-Interventional Study to Compare Digital Monitoring of Patients With Chronic Spontaneous Urticaria by Telemedicine to Face-to-Face Visits in Germany (DigiMoc)

Acronym: DigiMoc

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
May 28, 2025
Registry last updated
Jul 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.